Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages

Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages

Cross-neutralization is generally a prerequisite for cross-protection of vaccines against diseases caused by heterologous viruses. Using sera obtained from a randomized clinical phase 3 trial in adults, we investigated the cross-neutralization activity of VLA1553, a vaccine recently approved to prev...

Full description

Saved in:
Bibliographic Details
Main Authors: Karin Kosulin, Trevor L. Brasel, Jeanon Smith, Maricela Torres, Annegret Bitzer, Katrin Dubischar, Vera Buerger, Robert Mader, Scott C. Weaver, David W.C. Beasley, Romana Hochreiter
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Emerging Microbes and Infections
Subjects:
Chikungunya virus
vaccine
VLA1553
cross-neutralization
CHIKV lineages
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2025.2469653
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2025.2469653

Similar Items